# The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

> **NCT05990985** · NA · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 20 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Mitoxantrone hydrochloride liposome injection
- **DRUG:** RiTUXimab Injection
- **DRUG:** Cyclophosphamid
- **DRUG:** Vincristine
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT05990985
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-08-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05990985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05990985, "The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05990985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*